Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

UFT in gastric cancer: current status and future developments

A R Hanauske1

  • 1I Department of Medicine, Klinikum Rechts der Isar, Munich, Germany.

Oncology (Williston Park, N.Y.)
|February 12, 1998
PubMed
Summary

Tegafur and uracil (UFT) shows promise in advanced gastric cancer treatment, offering a 47% 1-year survival rate as a single agent. Further evaluation of UFT combinations is ongoing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.

International journal of clinical pharmacology and therapeutics·2005
Same author

Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.

International journal of clinical pharmacology and therapeutics·2005
Same author

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.

European journal of cancer (Oxford, England : 1990)·2003
Same author

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Investigational new drugs·2002
Same author

Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.

Cancer chemotherapy and pharmacology·2002
Same author

In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.

Investigational new drugs·2001

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Advanced gastric cancer has a poor prognosis despite surgical and chemotherapeutic advances.
  • Current treatments, including fluorouracil (5-FU) and cisplatin combinations, show limited long-term survival benefits.
  • Tegafur and uracil (UFT) has demonstrated clinical activity in gastric cancer, particularly in Japan.

Purpose of the Study:

  • To review the efficacy and safety of tegafur and uracil (UFT) in advanced gastric cancer.
  • To summarize UFT's use as a single agent and in combination regimens.
  • To evaluate UFT's role in neoadjuvant and adjuvant settings for gastric cancer.

Main Methods:

  • Review of clinical studies on tegafur and uracil (UFT) in advanced gastric cancer.
  • Analysis of data from Japan and ongoing European trials.
  • Assessment of UFT in monotherapy, combination therapy, neoadjuvant, and adjuvant settings.

Main Results:

  • Single-agent UFT therapy achieved a 47% 1-year survival rate in responding patients.
  • UFT has been safely combined with various agents in Japanese studies.
  • European studies are investigating UFT combination regimens.

Conclusions:

  • Tegafur and uracil (UFT) is a viable option for advanced gastric cancer treatment.
  • Further research is needed to determine the precise contribution of UFT in combination therapies.
  • UFT shows potential in neoadjuvant and adjuvant settings, warranting further investigation.

Related Experiment Videos